The efficacy and safety of mirabegron in treating ureteral stent‐related symptoms: A systematic review and meta‐analysis

Objectives This meta‐analysis aimed to assess the efficacy and safety of mirabegron in treating ureteral stent‐related symptoms. Methods MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched to identify randomized controlled trials (RCT) of mirabegron in treating ureteral stent‐...

Full description

Saved in:
Bibliographic Details
Published in:Lower urinary tract symptoms 2022-01, Vol.14 (1), p.27-34
Main Authors: Li, Zhouyue, Cui, Yuanshan, Chai, Yumeng, Zhang, Yong
Format: Article
Language:English
Subjects:
Acetanilides - adverse effects
Humans
lower urinary tract symptoms
Male
Meta-analysis
mirabegron
Stents - adverse effects
Systematic review
Thiazoles - adverse effects
Treatment Outcome
Ureter
ureteral stent
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives This meta‐analysis aimed to assess the efficacy and safety of mirabegron in treating ureteral stent‐related symptoms. Methods MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched to identify randomized controlled trials (RCT) of mirabegron in treating ureteral stent‐related symptoms. We conducted a systematic review and meta‐analysis based on the eligible RCT. Results Five RCT including 546 patients and comparing mirabegron with placebo or blank control were involved in the present research. Regarding efficacy, mirabegron was superior to controls in urinary symptom score (P = .0006) and general health score (P 
ISSN:1757-5664
1757-5672
DOI:10.1111/luts.12405